← Back to all trials
Not Yet Recruiting
NCT07807826
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3)
Conditions: Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 240
Sponsor: Beijing Keymed Biosciences Co., Ltd.
Location: Beijing Tongren Hospital, CMU Beijing Beijing Municipality
Summary
This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM512, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and immunogenicity of CM512 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)
Eligibility Criteria
Inclusion Criteria:
* with chronic rhinosinusitis with nasal polyposis (CRSwNP)
* Nasal Polyp Score (NPS) of ≥5 with a minimum score of 2 in each nasal cavity
* Nasal Congestion Score of 2 or 3 at screening period, and at least 2 at baseline
* Contraception
Exclusion Criteria:
* Not enough washing out period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for Interleukin (IL)-4 receptor alpha subunit antagonists, less than 8 weeks or 5 half-lives for systemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy).With malignant or benign tumor of nasal cavity
Source: ClinicalTrials.gov (NCT07807826). StuddyBuddy aggregates publicly available trial information.
